Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP448809.RACZIIpnFh7t_p0vr45LICkm25yrAoRZ0qCB6U0RWAUs8130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP448809.RACZIIpnFh7t_p0vr45LICkm25yrAoRZ0qCB6U0RWAUs8130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP448809.RACZIIpnFh7t_p0vr45LICkm25yrAoRZ0qCB6U0RWAUs8130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP448809.RACZIIpnFh7t_p0vr45LICkm25yrAoRZ0qCB6U0RWAUs8130_provenance.
- NP448809.RACZIIpnFh7t_p0vr45LICkm25yrAoRZ0qCB6U0RWAUs8130_assertion description "[Eight patients, five with pituitary carcinomas (three prolactin (PRL) and two ACTH) and three with aggressive pituitary tumors (one PRL and two ACTH), all treated with temozolomide administered orally for four to 24 cycles, were included in our French multicenter study.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP448809.RACZIIpnFh7t_p0vr45LICkm25yrAoRZ0qCB6U0RWAUs8130_provenance.
- NP448809.RACZIIpnFh7t_p0vr45LICkm25yrAoRZ0qCB6U0RWAUs8130_assertion evidence source_evidence_literature NP448809.RACZIIpnFh7t_p0vr45LICkm25yrAoRZ0qCB6U0RWAUs8130_provenance.
- NP448809.RACZIIpnFh7t_p0vr45LICkm25yrAoRZ0qCB6U0RWAUs8130_assertion SIO_000772 20660056 NP448809.RACZIIpnFh7t_p0vr45LICkm25yrAoRZ0qCB6U0RWAUs8130_provenance.
- NP448809.RACZIIpnFh7t_p0vr45LICkm25yrAoRZ0qCB6U0RWAUs8130_assertion wasDerivedFrom befree-20140225 NP448809.RACZIIpnFh7t_p0vr45LICkm25yrAoRZ0qCB6U0RWAUs8130_provenance.
- NP448809.RACZIIpnFh7t_p0vr45LICkm25yrAoRZ0qCB6U0RWAUs8130_assertion wasGeneratedBy ECO_0000203 NP448809.RACZIIpnFh7t_p0vr45LICkm25yrAoRZ0qCB6U0RWAUs8130_provenance.
- befree-20140225 importedOn "2014-02-25" NP448809.RACZIIpnFh7t_p0vr45LICkm25yrAoRZ0qCB6U0RWAUs8130_provenance.